University of British Columbia, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Vancouver, British Columbia, Canada.
University of British Columbia, Faculty of Medicine, Vancouver, British Columbia, Canada.
J Low Genit Tract Dis. 2018 Jul;22(3):212-218. doi: 10.1097/LGT.0000000000000399.
The aim of the study was to determine regression rates of cervical intraepithelial neoplasia (CIN) 2 and 3 in women younger than 24 years, followed conservatively for up to 24 months.
This is a retrospective chart review of colposcopy patients in clinic database based on the following: (1) younger than 24 years at first visit; (2) first visit January 1, 2010, to May 31, 2013, and at least 1 follow-up visit after diagnosis; (3) histologic diagnosis of CIN2+; and (4) optimal conservative management (observation for up to 24 months or to 24 years, whichever occurred first). Patient information and clinical/pathologic data were extracted from charts to examine patient characteristics and treatment outcomes, CIN2+ regression rates, median times to regression for CIN2 versus CIN3 (Kaplan-Meier survival analysis), and predictors of regression (multivariate logistic regression analysis).
A total of 154 women met criteria. The most severe histological diagnoses were CIN2 in 99 (64.3%), CIN3 in 51 (33.1%), and adenocarcinoma in situ in 4 (2.6%). Adenocarcinoma in situ was immediately treated. In follow-up, CIN2 regressed to CIN1 or negative in 74 women (74.7%)-median time to regression, 10.8 months. Cervical intraepithelial neoplasia 3 regressed in 11 women (21.6%)-median time to regression not reached (last follow-up censored at 52.7 months). Cervical intraepithelial neoplasia 2 on biopsy, low grade referral Pap, and younger age predicted regression. Overall, 49 women (31.8%) were treated.
Conservative management should continue to be recommended to young women with CIN2. Rigorous retention mechanisms are required to ensure that these women return for follow-up.
本研究旨在确定对 24 岁以下行保守治疗的宫颈上皮内瘤变(CIN)2 和 3 患者的消退率,随访时间最长达 24 个月。
这是一项基于以下条件的回顾性图表分析:(1)初诊时年龄<24 岁;(2)初诊时间为 2010 年 1 月 1 日至 2013 年 5 月 31 日;(3)组织学诊断为 CIN2+;(4)采用最佳保守治疗(观察最长 24 个月或至 24 岁,以先到者为准)。从图表中提取患者信息和临床/病理数据,以检查患者特征和治疗结局、CIN2+消退率、CIN2 和 CIN3 消退的中位时间(Kaplan-Meier 生存分析),以及消退的预测因素(多变量逻辑回归分析)。
共 154 名女性符合标准。最严重的组织学诊断为 CIN2 99 例(64.3%)、CIN3 51 例(33.1%)和原位腺癌 4 例(2.6%)。原位腺癌立即接受治疗。在随访中,CIN2 消退为 CIN1 或阴性的有 74 例(74.7%)-中位消退时间为 10.8 个月。CIN3 消退的有 11 例(21.6%)-中位消退时间未达到(最后一次随访在 52.7 个月时删失)。活检为 CIN2、低级别转诊巴氏涂片和年龄较小预测消退。总体而言,49 名女性(31.8%)接受了治疗。
应继续向 CIN2 年轻女性推荐保守治疗。需要严格的保留机制来确保这些女性返回接受随访。